ACB - Aurora Cannabis Inc.
A Q1 FY2027 revenue record from Tilray Brands (NASDAQ:TLRY) is drawing heavy selling, because the segment that built the company's following moved the wrong way. Tilray Brands shares are at $3.
NASDAQ | TSX: ACB Multi-million-dollar investment results in increased domestic production capacity in Germany, more than doubling expected annual flower output. Enhanced facility adopts Aurora's proven cultivation practices and proprietary genetics to support consistent, high-quality production.
Aurora's Special Committee will commence a thorough and independent review of the revised Hostile Bid and the Board will provide a formal recommendation to shareholders once the review is complete. Shareholders are advised to TAKE NO ACTION pending a formal recommendation.
The multi-year cannabis sector bear market is starting to give way to a calculated wave of industry consolidation. Behind the urge to merge is a significant shift in U.S. federal regulatory policy, encouraging better-capitalized operators to secure global supply chains before tax relief drives widespread multiple expansion.
NASDAQ | TSX: ACB Curaleaf has yet to file a Notice of Variation and Change to revise its offer. Once filed, the Special Committee will complete a thorough and comprehensive review prior to issuing a formal recommendation to shareholders Aurora's application to the Alberta Securities Commission delivered results for shareholders: Curaleaf's latest update indicates that Aurora shareholders will be provided with pro forma financials and a bid timeline that complies with securities laws Questions about the Hostile Bid or would like to stay informed?
Shares of Aurora Cannabis Inc. (TSE: ACB - Get Free Report) rose 15.6% on Monday. The stock traded as high as C$6.51 and last traded at C$6.45. Approximately 914,036 shares traded hands during trading, an increase of 122% from the average session volume of 410,815 shares. The stock had previously closed at C$5.58. Analyst Ratings Changes
Aurora Cannabis Inc. (NASDAQ: ACB - Get Free Report) was the recipient of some unusual options trading activity on Monday. Traders acquired 2,710 call options on the stock. This is an increase of approximately 248% compared to the average daily volume of 778 call options. Aurora Cannabis Stock Up 15.2% NASDAQ: ACB traded up $0.59 during trading
Curaleaf Hldgs Inc. (OTCQX:CURLF), the Connecticut-based cannabis company, has raised its offer for Aurora Cannabis Inc (TSX:ACB, NASDAQ:ACB), a Canadian cannabis producer, by 25% to a total implied value of $5 per Aurora share in cash and stock. The new price is 86% above Aurora's 30-day volume-weighted average share price of $2.75 as of August 10, the day before Curaleaf announced its intention to make its initial offer.
ProPhase Labs (NASDAQ: PRPH - Get Free Report) and Aurora Cannabis (NASDAQ: ACB - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability. Institutional and Insider Ownership 9.4% of ProPhase
Curaleaf presented an unsolicited offer to buy Aurora Cannabis for $4 per share. Aurora rejected the offer, saying it didn't fully value Aurora's business.
NASDAQ | TSX: ACB Aurora has filed an application with the Alberta Securities Commission for an order requiring Curaleaf to comply with securities laws. Aurora intends to demonstrate that Curaleaf's Circular has not satisfied several regulatory requirements, impacting Aurora Shareholders, including providing pro-forma financials and keeping the hostile bid open for the minimum period.
NASDAQ| TSX: ACB Re-affirms FY27 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA 1 Following the receipt of EU-GMP certification in July, Safari Flower Company is expected to contribute incremental net revenue and adjusted EBITDA 1 Continued strong performance in Germany and Poland, contributing to profitable international growth expectations and leadership positions in the two largest EU markets, including #1 market share by revenue in Poland UK market expansion underway, with recently announced acquisition of Internode Pharma and HAP Pharma Limited expected to support further market share growth EDMONTON, AB, Sept. 16, 2026 /PRNewswire/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the leading Canadian-based global medical cannabis company, today provided a business update, highlighting the expected additional benefits of the Safari Flower Company acquisition, continued strong performance in key high margin international markets, and reaffirmed its fiscal year 2027 Q2 guidance.
Cross-border consolidation in the cannabis industry has moved from executive speculation into aggressive dealmaking. As regulatory hurdles begin to clear across North America and Europe, operators are moving quickly to strengthen their finances and expand globally.
Aurora Cannabis Refutes Curaleaf's Latest Attempt To Distract Shareholders From The FactsPR NewswireEDMONTON, AB, Sept. 14, 2026NASDAQ | TSX: ACBCuraleaf's anno
NASDAQ | TSX: ACB Curaleaf's announcement is a desperate effort to shift attention away from the fundamental issue facing shareholders: its inadequate hostile bid undervalues Aurora. Curaleaf's attempt to fabricate issues ignores the reality of its own balance sheet: more than $1 billion of debt1, including $500 million carrying an 11.5% interest rate, exposing shareholders to significant financial and dilution risks.
Options-income ETFs now offer monthly payouts that dwarf what traditional dividend stocks provide, but before you move a dollar, there are tax mechanics and capital preservation risks that most income investors completely overlook.
EDMONTON, AB, Sept. 9, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Faris El Refaie, a biopharmaceutical leader with 25 years of experience, will join the company as Executive Vice President, Global Commercial, effective September 28, 2026.
Curaleaf Responds to Aurora Circular; Reaffirms Offer as the Best Path to Value Creation for Shareholders PR Newswire
Aurora Cannabis is urging its shareholders to reject an unsolicited $272 million hostile takeover bid from Curaleaf Holdings.
NASDAQ | TSX: ACB Curaleaf's hostile and opportunistic bid significantly undervalues Aurora, and aims to capture Aurora's assets at a discount Aurora is debt free and holds $149 million in cash 1 , Curaleaf carries over $1 billion in debt 2 , Aurora shareholders' own cash should not be used to help fix Curaleaf's balance sheet The hostile bid exposes Aurora shareholders to significant risks not fairly disclosed and could meaningfully weaken shareholder rights Aurora's transformation into a global, high-margin medical cannabis leader is delivering results, and the Board believes significant value creation lies ahead Aurora Files Directors' Circular Unanimously Recommending Shareholders REJECT Curaleaf's Hostile Bid by TAKING NO ACTION and NOT TENDERING their shares To keep current with and obtain information about the hostile bid, please visit www.ProtectAurora.com EDMONTON, AB, Sept. 2, 2026 /PRNewswire/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the leading Canadian-based global medical cannabis company, today urged shareholders to reject the unsolicited take-over bid ("Hostile Bid") from Curaleaf Holdings, Inc. ("Curaleaf") (TSX: CURA) (OTCQX: CURLF), warning that the Hostile Bid would put Aurora shareholders' value and future upside at risk.